1-20 of 28346
Sort by
Image
Published: 25 April 2025
Figure 3. Kaplan–Meier curves (unadjusted) showing time from index date (statin initiation) to any inflammatory bowel disease (IBD)-related disease flare in patients with ulcerative colitis (UC) and Crohn’s disease (CD) comparing statin users and non-users. Number of events is shown in the parenthesis. (Log-r
Image
Published: 25 April 2025
Figure 2. Alternative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry pathway molecules are not significantly modulated in the intestinal mucosa of inflammatory bowel disease (IBD) patients. The mRNA expression levels of AGTR1 (A) and ADAM17 (B) were evaluated by RT-PCR, comparing results b
Image
Published: 25 April 2025
Figure 4. Increased circulating mannose-binding lectin (MBL) levels in inflammatory bowel disease (IBD) patients compared to healthy individuals. Circulating MBL levels were measured in total IBD (A), Crohn’s disease (CD), or ulcerative colitis (UC) (B), and patients were stratified by treatment, compared to
Image
Published: 25 April 2025
Figure 1. Kaplan–Meier curves (unadjusted) showing time from index date (statin initiation) to any inflammatory bowel disease (IBD)-related surgical event in patients with ulcerative colitis (UC) and Crohn’s disease (CD) comparing statin users and non-users. Number of events is shown in the parenthesis. (Log-
Image
Published: 25 April 2025
Figure 2. Kaplan–Meier curves (unadjusted) showing time from index date (statin initiation) to any inflammatory bowel disease (IBD)-related hospitalization in patients with ulcerative colitis (UC) and Crohn’s disease (CD) comparing statin users and non-users. Number of events is shown in the parenthesis. (Log
Image
Published: 25 April 2025
Figure 3. Impact of biologic medications on circulating sACE2 levels in inflammatory bowel disease (IBD) patients. Serum concentration of sACE2 was evaluated in (A) total IBD patients, (B) Crohn’s disease (CD) or ulcerative colitis (UC) patients versus healthy donors (HDs), (C) IBD patients stratified by medi
Journal Article
Hamed Khalili and others
Inflammatory Bowel Diseases, izaf077, https://doi.org/10.1093/ibd/izaf077
Published: 25 April 2025
Journal Article
Laura Francesca Pisani and others
Inflammatory Bowel Diseases, izaf079, https://doi.org/10.1093/ibd/izaf079
Published: 25 April 2025
Image
Published: 25 April 2025
Figure 1. Reduced expression of angiotensin-converting enzyme 2 (ACE2) and host cell priming proteases on the intestinal mucosa of inflammatory bowel disease (IBD) patients. Analysis of ACE2 (A), TMPRSS2 (B), and TMPRSS4 (C) gene expression in total IBD, Crohn’s disease (CD), and ulcerative colitis (UC) patie
Journal Article
Jimmy K Limdi
Inflammatory Bowel Diseases, izaf081, https://doi.org/10.1093/ibd/izaf081
Published: 23 April 2025
Journal Article
Marco Vincenzo Lenti and others
Inflammatory Bowel Diseases, izaf065, https://doi.org/10.1093/ibd/izaf065
Published: 21 April 2025
Journal Article
Inflammatory Bowel Diseases, izaf075, https://doi.org/10.1093/ibd/izaf075
Published: 17 April 2025
Journal Article
Perseus V Patel and Alka Goyal
Inflammatory Bowel Diseases, izaf049, https://doi.org/10.1093/ibd/izaf049
Published: 16 April 2025
Journal Article
Katrina S Hacker and Alana Friedlander
Inflammatory Bowel Diseases, izaf059, https://doi.org/10.1093/ibd/izaf059
Published: 16 April 2025
Journal Article
Laurie B Grossberg and others
Inflammatory Bowel Diseases, izaf016, https://doi.org/10.1093/ibd/izaf016
Published: 13 April 2025
Journal Article
Osman Cagin Buldukoglu and others
Inflammatory Bowel Diseases, izaf074, https://doi.org/10.1093/ibd/izaf074
Published: 13 April 2025
Image
Published: 12 April 2025
Figure 1. Attrition flow diagram indicating inclusion and exclusion criteria for cohort selection. a Codes could be from 2 outpatients (≥30 to ≤365 days apart) or ≥1 inpatient (≥30 to ≤365 days apart) ICD-9/10 diagnosis code for UC (K51.X). b Treatment must have occurred ±30 days from index date; convention
Image
Published: 12 April 2025
Figure 3. IR per 1000 PYs for (A) fungal and viral infections, (B) cardiac, vascular, and circulatory disorders, (C) hepatobiliary injury/disorders, (D) malignancies, (E) eye disorders for the UC overall, UC advanced therapy, UC trial-similar, and Non-UC cohorts assessed, stratified by age. *Indicates signifi
Journal Article
Miguel D Regueiro and others
Inflammatory Bowel Diseases, izaf067, https://doi.org/10.1093/ibd/izaf067
Published: 12 April 2025
Image
Published: 12 April 2025
Figure 2. IR per 1000 PYs for (A) fungal and viral infections, (B) cardiac, vascular, and circulatory disorders, (C) hepatobiliary injury/disorders, (D) malignancies, (E) eye disorders for the UC overall, UC advanced therapy, UC trial-similar, and Non-UC cohorts. *Indicates significant differences as determin